GINZA NOA CLINIC
Tokyo, Japan International Patient Support
Contact Us

Are All Exosome Products Equivalent?

No. Products sold as exosomes should not be assumed to be equivalent or interchangeable. They can differ in source cells, composition, manufacturing, storage, and evidence for a particular use. Matching particle counts or the words “stem cell-derived” does not establish the same quality, safety, or clinical effect.

In its December 6, 2019 notification, the U.S. Food and Drug Administration (FDA) reported serious adverse events after unapproved products marketed as containing exosomes and stated that there were no FDA-approved exosome products Public safety notification exosome products. A 2024 knee osteoarthritis trial enrolled 31 patients, but found no statistically significant advantage for one placental extracellular-vesicle preparation over saline: symptoms were assessed at 2 and 6 months, and MRI at 6 months S12891 024 07979 w. Neither a shared label nor evidence about one preparation establishes what another will do.

Are All Exosome Products Equivalent?

What an exosome product contains

An exosome is a membrane-bound particle released by a cell, not a living stem cell. Stem cells can self-renew and develop into specialized cells; exosomes cannot divide or become replacement tissue. They can carry proteins, lipids, and RNA that affect communication between cells Stc basicsPMC10850029.

Extracellular vesicle, or EV, is the broader term. Exosomes are EVs formed through the endosomal pathway inside cells. Size alone does not establish that origin. MISEV2023 research guidance recommends using EV terminology when a more specific origin has not been demonstrated PMC10850029.

Conditioned medium is the liquid collected after cells have been cultured. It can contain EVs, soluble proteins, and leftover medium components. The secretome is the mixture of substances cells release; exosomes are only one possible component PMC6562906. These terms do not describe interchangeable preparations.

What the offer may contain What still needs checking
Whole conditioned medium Which substances remain in the liquid, and how its composition and safety were tested
EV-enriched fraction How vesicles were concentrated, and what non-vesicular material remains
Characterized EV preparation Which identity, purity, activity, and stability tests were performed; characterization alone does not establish clinical benefit

Why source and manufacturing matter

Source cells may come from bone marrow, fat, umbilical cord, or other tissues. Donor characteristics, cell culture conditions, and passage history—the number of times cells are moved into fresh culture vessels—can change what the cells release. Animal serum used in culture can also introduce vesicles and proteins that are difficult to remove completely PMC10850029PMC6562906.

Separation methods do not produce identical mixtures. Ultracentrifugation can collect non-vesicular material along with EVs; size-based methods separate by size, not by biological origin. Concentrating a liquid does not by itself establish purity PMC10850029.

Ask for product-specific specifications covering identity, composition, sterility, endotoxin, biological activity, and storage. A document showing particle count alone cannot answer all of these questions. Freezing, thawing, transport, and storage can affect an EV preparation, so stability evidence must match the actual handling conditions PMC10850029.

These are safety questions, not just laboratory details. FDA consumer guidance, marked current as of April 8, 2024, warns about unapproved regenerative products and contamination during preparation, including bacteria, viruses, or mold Important patient and consumer information about regenerative medicine therapies. The CDC's December 2019 account describes serious adverse events, including bacterial infections, in Nebraska patients who received products marketed as containing exosomes Stem cell products. These reports do not establish a complication rate for every EV product.

Japan's Ministry of Health, Labour and Welfare (MHLW) issued a notice on July 31, 2024 calling for particular attention to safety when using stem cell culture supernatant and exosome-related products 001281987.pdf. Japanese Society for Regenerative Medicine (JSRM) guidance identifies risks including infection, unwanted immune responses, impurities, unintended distribution, and changes associated with preparation, transport, and storage News14993 2.pdf.

Why particle counts cannot rank products

A particle count records what a measurement method detects. It does not establish that every detected particle is an exosome, identify its cargo, or show that it has the intended biological activity. Total protein also measures bulk material rather than a proven active ingredient. Two vials with the same count can differ in composition and activity PMC10850029.

Potency means biological activity measured in a defined test. It must relate to the preparation and its intended purpose; there is no single count-to-potency conversion that makes all EV preparations interchangeable. A higher particle count alone does not establish greater benefit or safety PMC10850029News14993 2.pdf.

For example, the knee trial discussed here used 5 mL at 7 x 10^9 particles per mL S12891 024 07979 w. That describes its investigational preparation, not a recommended dose for another product, disease, or route. A seller's matching number does not demonstrate equivalence.

What the human evidence shows

Laboratory and animal findings can support further research, but cannot establish that an injection benefits people with a particular disease PMC10850029PMC6562906. Human evidence needs to match the product, condition, route, and treatment schedule being offered.

In the 2024 randomized, triple-blind trial by Bolandnazar and colleagues in Iran, adults had bilateral grade 2–3 knee osteoarthritis. One knee received a single intra-articular injection of 5 mL of placental mesenchymal stromal cell-derived EVs; the other received 5 mL of saline S12891 024 07979 w.

The trial enrolled 31 patients with 62 knees. The six-month analysis included 29 patients with 58 knees: 28 women and 1 man, with a mean age of approximately 55 years. EV-treated knees showed no statistically significant advantage over saline-treated knees on symptom measures at 2 or 6 months, or MRI findings at 6 months S12891 024 07979 w.

No systemic complications or severe local reactions were reported. However, a small study with six months of follow-up cannot establish broad safety or exclude uncommon or delayed harms. Its negative efficacy result does not prove that every EV preparation is ineffective; it also gives no basis for claiming that a different commercial product works S12891 024 07979 w.

Judge evidence for the preparation tested, in the condition and route tested, over the follow-up studied. The word exosome is not a bridge between otherwise different products.

A trial registration shows that a study was registered, not that it succeeded. Publication or PubMed indexing does not remove design limitations. Look for the comparison group, number of patients—not just the number of treated joints—outcomes, follow-up, and reported adverse events.

What regulatory claims mean

The FDA's December 2019 exosome notification states that there were no FDA-approved exosome products Public safety notification exosome products. Its consumer guidance also warns about unapproved regenerative products Important patient and consumer information about regenerative medicine therapies. These are dated regulatory statements, not a comprehensive approval search for November 2026. For a current claim, ask for the exact product and indication and verify them with the regulator in the country of treatment.

Japan's July 31, 2024 MHLW notice stated that, at that time, no medicines using the exosome-related materials it described had demonstrated efficacy and safety and obtained marketing approval, including overseas 001281987.pdf. That is the notice's dated statement, not a claim that an exhaustive current global approval search has been performed.

A clinic's cell-treatment provision plan is not evidence that an exosome injection is approved or effective. JSRM's 2024 guidance specifically described the unapproved EV preparations discussed there as outside Japan's regenerative-medicine safety-law framework at that time News14993 2.pdf. Do not transfer a registration claim for a cell-based service to a cell-free product.

The site's regenerative medicine overview, registration and compliance explainer, and treatment process explainer provide context for cell-based care. They are not independent evidence of exosome approval or benefit. Ask which legal route applies to the exact preparation, rather than accepting “government registered” as an efficacy claim.

Risks of assuming equivalence

Cell-free does not mean sterile, free of immune effects, or clinically proven. Potential risks include infection, impurities, unwanted immune responses, and unintended distribution Important patient and consumer information about regenerative medicine therapiesNews14993 2.pdf. Exosomes cannot themselves divide, but that does not establish that all downstream effects on recipient cells are harmless.

The site's safety explainer provides broader context; verify product-specific claims against regulator documents and relevant studies. A further risk is delaying established treatment, rehabilitation, or evaluation while pursuing an unproven intervention.

Testimonials cannot separate a product's effects from natural recovery, placebo effects, other treatments, or selective reporting. They also cannot establish the quality of a later batch.

How to compare two offers

Consider a hypothetical comparison, not a patient case: both offers say “stem cell-derived exosomes” and advertise the same particle count. One supplies only a brochure. The other supplies batch documentation and a human study. The extra documents make the second offer easier to assess; they do not automatically make it effective or equivalent to the study preparation. Check the named manufacturer, source cells, process, dose, route, diagnosis, and handling conditions before relying on the study PMC10850029News14993 2.pdf.

Use the same questions for both providers:

  1. What is in the vial? Conditioned medium, an EV-enriched fraction, or a characterized EV preparation? What supports the exosome label?
  2. Which source cells were used? Ask about tissue source, donor screening, autologous or allogeneic origin, passage history, and culture materials.
  3. What batch evidence is available? Request identity, composition, sterility, endotoxin, and activity results, plus the batch identifier. A cell processing center description is not a substitute for finished-product documentation.
  4. What does the dose mean? Ask for volume, measurement method, particle or protein concentration, and any relevant potency test. Check storage, transport, and expiry conditions.
  5. Does the human study match the offer? Compare product, diagnosis and disease stage, route, schedule, comparison group, outcomes, follow-up, and harms. Joint injections, intravenous infusions, and eye drops cannot borrow one another's evidence.
  6. What exactly is the regulatory claim? Request the product name, country, claimed approval and indication, and a regulator record. If a plan number is offered instead, ask what it actually covers.
  7. What happens if there is a problem? Ask who provides follow-up, how adverse events are handled, and which symptoms require urgent care.
  8. What established options would this replace or delay? Discuss this with a physician who knows your diagnosis. General eligibility and exclusion factors are background information, not individual clearance for an EV intervention.

If a study or batch record is unavailable, record the answer as “not demonstrated.” Do not fill that gap with a particle count, a testimonial, or an assumption that all products with the same label work alike.

The bottom line

Exosome products are not automatically equivalent. The 2024 knee trial enrolled 31 patients and analyzed 29 at six months, without finding a statistically significant advantage over saline for its particular preparation S12891 024 07979 w. That is a reason to examine exact-product evidence, not to infer benefit or failure for every other vial.

Compare composition, quality controls, handling, and human evidence for the intended use. When those details do not match or are missing, clinical interchangeability has not been demonstrated.

If you are comparing a specific offer, you can send your questions through the contact page. Contact Us

This is an evidence-based explanation, not a report of first-hand patient care or product testing. It summarizes the cited studies and dated regulatory documents; it is not a diagnosis or treatment recommendation. Discuss care with a licensed physician who has reviewed your records.